Dr. Francis Collins, director of The National Institutes of Health, recently featured Hesperos technology on his blog. In the post, Dr. Collins reviews a published study where Hesperos researchers investigated and treated several cancer lines with existing chemotherapeutics. The study both treated the cancer while reproducing known toxic effects of specific drugs and their more … Read more
Hesperos, Inc., (www.hesperosinc.com) announced today the University of Central Florida (UCF) received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. “We are grateful to have funding to support research in an area that represents such a large and growing need,” said Dr. … Read more
HUMAN-ON-A-CHIP PREDICTS IN VIVO RESULTS BASED ON IN VITRO MODEL FOR THE FIRST TIME Hesperos’ integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms preclinically and replicate results seen in in vivo studies (ORLANDO, Fla.) — Hesperos Inc., pioneers of the “human-on-a-chip” in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known … Read more
In vitro multi-organ system by Hesperos, Inc. realistically replicates the responses of cancer treatments and has potential to inform treatment decisions. ORLANDO, FLA – June 19, 2019 — A reconfigurable “body-on-a-chip” model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organs, such as the heart and … Read more
The interest in our human-on-a-chip model continues to grow. Last week we brought our systems to the National Center for Translational Science (NCATS) at the NIH in Washington, D.C. to perform a real-time demo using live cells. Hesperos, Inc. is the first company spun out from the Tissue Chip Program at NCATS. In attendance were … Read more
HESPEROS’ MULTI-ORGAN “HUMAN-ON-A-CHIP” SYSTEM FOUND EFFECTIVE FOR LONG-TERM TOXICOLOGY TESTING Collaboration between L’Oreal, Hesperos and UCF results in further reduction in reliance on animal testing in drug and cosmetics development (ORLANDO, Fla.) The replacement of animals as test subjects is one step closer to reality with the successful testing of multi-organ “human-on-a-chip” models to recapitulate … Read more
HESPEROS AT NCATS-NASA STATE-OF-THE-SCIENCE MEETING We’ve been forging new frontiers with our human-on-a-chip multi-organ models—could the next one take us into space? Last month, we traveled to Washington, DC, to attend a workshop with officials from NASA,NCATS (National Center for Advancing Translational Sciences), and other government officials for a “State-of-the-Science” meeting on 3D tissues and … Read more
We were proud to join hundreds of Florida’s executives, scientists, researchers, investors, legislators, and service providers from the biopharmaceutical, medical device, and healthIT at the recent BioFlorida Annual Conference to celebrate Florida innovation and achievements — and to share some of our own. The conference, held in Ft. Lauderdale on October 14-16, addressed distinct areas … Read more
(ORLANDO, Fla.) Hesperos, Inc. has announced that it has been named one of the 50 statewide companies expected to see significant growth over the next several years by GrowFL. The 50 companies were selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association … Read more
ORLANDO, FLA – September 6, 2018 — Hesperos, Inc. announced today the receipt of a $4 million three-year NIH Phase IIb Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to increase capacity for its novel human-on-a-chip technology, and prepare its systems for regulatory … Read more